A wave of nine‑figure private financings signaled renewed investor appetite for late‑stage and platform biotechs, with multiple companies disclosing large rounds that pushed weekly totals higher. Endpoints and industry trackers described the activity as a marker of a nascent biotech rebound, driven by clearer regulatory pathways and better clinical readouts across oncology and rare disease. Separately, ADC specialist Adcytherix closed a €105 million (US$122 million) Series A to push its lead ADC into clinical development next year. The financing underscores investor interest in differentiated conjugate platforms and the broader return of megaround‑style capital to private drug developers. Market participants noted that deal sizes remain concentrated among platform and oncology plays with near‑term data catalysts, suggesting a selective but meaningful recovery in venture funding.